Clinical Trial Update: Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated whether serum proteomic profiles can predict gemcitabine sensitivity in metastatic breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED